Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study

NCT02875548 is registered in ClinicalTrials.gov with Epizyme, Inc. as lead sponsor.

NCT NCT02875548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02875548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study
Lead sponsor
Epizyme, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
August 30, 2016
Completion date
September 26, 2025
Enrollment
58 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, diffuse large b-cell lymphoma (dlbcl), epitheliod sarcoma (es), follicular lymphoma (fl), mesothelioma, non-hodgkin lymphoma (nhl), renal medullary carcinoma, synovial sarcoma